Case Name: Allergan USA, Inc. v. MSN Labs. Private Ltd., C.A. Nos. 19-1727-RGA, 20-1479-RGA, 2023 WL 6295496 (D. Del. Sept. 27, 2023) (Andrews, J.) Drug Product and Patent(s)-in-Suit:.
The District Court for the District of Delaware recently held on summary judgment that a patent with 2,295 days of combined patent term adjustment (PTA) and patent term extension (PTE).
On September 27, 2023, Judge Richard Andrews, following a three-day bench trial, determined that several patents asserted by Allergan against Sun Pharmaceuticals and MSN Laboratories.
- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive.
Data illustrates AbbVie s commitment to providing research and innovative solutions that support patients with high disease burden and unmet needOral presentations address treatment of moderate to severe Crohn s disease, including